cHL COHORT ONLY: history of allogeneic transplantXx_NEWLINE_xXPrior liver transplantXx_NEWLINE_xXAnti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trialXx_NEWLINE_xXPatients must not have any history of organ transplant that requires use of immunosuppressivesXx_NEWLINE_xXPatients are not eligible if they have had or are planned for solid organ transplant; patients who have received allogeneic hematopoietic stem cell transplant are eligible if:\r\n* The transplant occurred at least 90 days prior to registration, \r\n* Patient has no prior acute graft versus host disease (GVHD), and \r\n* Within 48 hours of registration, patient demonstrates at least 90% engraftment, defined as: absolute neutrophil count (ANC) >= 500 mcl, measured over 3 consecutive days or 1 day with an ANC >= 1,000 mcl, or platelets >= 50,000 mcl measured, wherein the patient did not receive any platelet transfusions within 7 days prior to laboratory assessmentXx_NEWLINE_xXPrevious allogeneic bone marrow transplantXx_NEWLINE_xXPatients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trialXx_NEWLINE_xXPatients who previously received a solid organ transplantXx_NEWLINE_xXHistory of liver transplantXx_NEWLINE_xXHistory of organ allograftXx_NEWLINE_xXPatients with previous allogeneic bone marrow transplantXx_NEWLINE_xXPatients with any history of solid organ or bone marrow transplant will not be eligibleXx_NEWLINE_xXPatients may have received prior allogeneic transplant or autologous transplant; however, patients with prior allogeneic bone marrow transplant will be eligible only if both of the following conditions are met:\r\n* The transplant must have been performed >= 90 days prior to registration\r\n* The patient must not have >= grade 2 acute graft versus host disease (GvHD) or either moderate or severe limited chronic GvHD within 14 days prior to registrationXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXHas had an allogeneic tissue/solid organ transplant.Xx_NEWLINE_xXPrior allogeneic stem cell transplant or solid organ transplantXx_NEWLINE_xXHistory of allogenic bone marrow or solid organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of allogeneic bone marrow, stem-cell, or solid organ transplantXx_NEWLINE_xXPrevious allogeneic transplantXx_NEWLINE_xXSubject with a history of organ transplant or allogeneic bone marrow transplant;Xx_NEWLINE_xXPrior allogeneic bone marrow or solid organ transplantXx_NEWLINE_xXPrevious HCT or solid organ transplant.Xx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXNo prior organ allograftXx_NEWLINE_xXOrgan transplant recipients other than bone marrow transplantXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXPrior solid organ transplantXx_NEWLINE_xXHas had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplantXx_NEWLINE_xXPatients scheduled for a combined transplant (such as liver-kidney), or having a previous solid organ, bone marrow, or autologous islet cell transplant.Xx_NEWLINE_xXPatients who receive sirolimus (Rapamune®) as part of their transplant immunosuppression regimenXx_NEWLINE_xXHad an autologous transplant within 3 months of starting study drug treatment.Xx_NEWLINE_xXConsidered a potential transplant candidate; the attending/treating physician will determine transplant candidacy at the time of consentXx_NEWLINE_xXHas had an allogenic tissue/sold organ transplant.Xx_NEWLINE_xXHistory of major organ transplant (i.e., heart, lungs, liver, or kidney).Xx_NEWLINE_xXPrior solid organ or hematologic transplant.Xx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXOrgan transplant recipientsXx_NEWLINE_xXNo prior allogeneic transplant unless all of the following apply:\r\n* At least 5 years from time of transplant\r\n* Absence of clinically significant graft-versus-host disease (GVHD)\r\n* Not on immune suppression\r\n* Approval of overall PIXx_NEWLINE_xXHad a solid organ or allogeneic bone marrow transplantXx_NEWLINE_xXHas had an allogeneic tissue/solid organ transplantXx_NEWLINE_xXHistory of major solid organ transplant (i.e., heart, lungs, liver and kidney).Xx_NEWLINE_xXHistory of an allogeneic bone marrow transplant.Xx_NEWLINE_xXPrior allogeneic bone marrow transplant.Xx_NEWLINE_xXNo prior hematopoietic transplantXx_NEWLINE_xXPrior hematopoietic transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXParticipants who have received a previous allogeneic bone marrow transplantXx_NEWLINE_xXPreviously received a solid organ transplant or allogeneic progenitor/stem cell transplant.Xx_NEWLINE_xXParticipant has had a prior allogeneic transplant.Xx_NEWLINE_xXEXCLUSION - PROCUREMENT: History of solid organ transplantXx_NEWLINE_xXEXCLUSION - INFUSION: History of solid organ transplantXx_NEWLINE_xXSubjects with clinically significant cardiovascular disease, history of organ transplant or allogeneic bone marrow transplant, active known or history of autoimmune disease that might recur or major surgery within 28 days prior to the first dose or still recovering from prior surgery.Xx_NEWLINE_xXPrior solid organ transplant.Xx_NEWLINE_xXLiver transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXOrgan transplantXx_NEWLINE_xXOrgan transplant that requires the use of immunosuppressive treatment.Xx_NEWLINE_xXParticipants who are within 6 months of an allogeneic bone marrow transplantXx_NEWLINE_xXThe patient is receiving immunosuppressive therapy for prophylaxis following a prior organ transplant (solid organ or allogeneic stem cell) or management of immune-mediated toxicities due to immunotherapy. Low-dose corticosteroid (defined as < 10mg/day of prednisone or equivalent) therapy is permitted.Xx_NEWLINE_xXPatients must not have experienced confirmed progressive disease since the time of their transplantXx_NEWLINE_xXIf a patient fully meets criteria for Arm 1, but has a history of solid organ or bone marrow transplant, the patient will be eligible for Arm 2Xx_NEWLINE_xXHistory of prior solid organ or bone marrow transplantXx_NEWLINE_xXChemo-sensitive disease; patients with relapsed plasma cell leukemia may have received systemic therapy including an autologous transplant but it is not required; patients with relapsed multiple myeloma (MM) must have received prior systemic therapy including an autologous transplant; patient must be in at least a PR at the time of transplant; early relapse (VGPR) from complete response will be allowedXx_NEWLINE_xXResidual disease at the time of transplant or post-transplant relapse is defined as polymerase chain reaction (PCR) positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry, or increased blasts on bone marrow biopsy or in the peripheral blood; minimal residual disease (MRD) will be defined as detection in blood or marrow of any of the following:\r\n* Any leukemia-specific marker (such as t(12;21); t(9;22) or t(4;11)) documented in the patient’s leukemia cells pre-transplant on a post-transplant evaluation\r\n* A leukemia-specific phenotype (e.g. expression of markers including CD10 and/or CD19 or CD3 and/or CD4 or CD8) post-transplant at a level of ? 0.01%\r\n* Mixed donor chimerism (> 20%)Xx_NEWLINE_xXHistory of organ allograft including corneal transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXPrior autologous and/or allogeneic transplant is permitted although transplant must have occurred greater than 90 days prior to registrationXx_NEWLINE_xXResidual disease at the time of transplant (bulky or minimal) or post transplant relapse as evidenced by polymerase chain reaction (PCR) positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry or increased blasts on bone marrow biopsy or in the peripheral blood; minimal residual disease (MRD) will be defined as detection in blood or marrow of any of the following:\r\n* Any leukemia specific marker (such as t(9:22) or t(4:11)) documented in the patient’s leukemia cells pre transplant on a post transplant evaluation\r\n* An immune globulin rearrangement known to be a disease marker for this patient post transplant\r\n* A leukemia specific phenotype post transplant at a level of ? 0.01%\r\n* Mixed donor chimerism (any level)Xx_NEWLINE_xXAt least 3 months has elapsed from the time of transplant andXx_NEWLINE_xXthe subject has recovered from transplant-associated toxicities prior to the first dose of GSK525762, and For subjects with a prior history of allogeneic transplant,Xx_NEWLINE_xXPrior solid organ transplantXx_NEWLINE_xXHistory of organ transplantXx_NEWLINE_xXAny prior myeloablative transplant within the last 6 monthsXx_NEWLINE_xXReceipt of an allogeneic transplant within 6 months or an autologous transplant within the preceding 3 months; evidence of ongoing graft-versus-host disease (GVHD)Xx_NEWLINE_xXHas a history of primary immunodeficiency or an allogeneic organ transplantXx_NEWLINE_xXPrior liver transplantXx_NEWLINE_xXPrior allogeneic transplant if performed < 6 months prior to first dose of AMV564, if patient has active GVHD, or if patient has not been off immunosuppressiveXx_NEWLINE_xXPrevious allogeneic transplantXx_NEWLINE_xXPatients may not have had a prior autologous or allogeneic transplantXx_NEWLINE_xXThe patient must be approved for transplant by the treating transplant physician. This includes completion of their pre-transplant workup, as directed by standard Dartmouth Hitchcock Medical Center (DHMC) standard operating procedures (SOPs) (DHMC SOP – Pre-transplant Evaluation of Allogeneic Recipient).Xx_NEWLINE_xXTransaminases < 3 x normal at the time of transplant.Xx_NEWLINE_xXMeasurable  disease of multiple myeloma at the time specified by one of the following:\r\n* If no relapse prior to transplant, values obtained at the time of diagnosis\r\n* If disease relapse prior to transplant and the patient did not have treatment for the relapsed disease prior to transplant, the values obtained at the time of relapse immediately prior to the transplant. \r\n* If disease relapse prior to transplant and the patient did have treatment for the relapsed disease prior to transplant, the values obtained prior to this therapy, ie, the time of relapseXx_NEWLINE_xXHistory of organ transplant that requires use of immunosuppressivesXx_NEWLINE_xXPrior allogeneic bone marrow transplant within 12 months of screening dateXx_NEWLINE_xXSolid organ or tissue transplant including stem cell transplantXx_NEWLINE_xXPrior allogeneic transplant of any solid organ or bone marrow/stem cellsXx_NEWLINE_xXOrgan transplant recipientXx_NEWLINE_xXPrior allogeneic transplant for any hematopoietic disorderXx_NEWLINE_xXHas undergone an organ transplant that requires use of immunosuppressive treatmentXx_NEWLINE_xXHistory of primary immunodeficiency, history of allogeneic organ transplant that requires therapeutic immunosuppressionXx_NEWLINE_xXPrior allogeneic transplant, within the last 5 yearsXx_NEWLINE_xXAny solid organ transplant or bone marrow transplantXx_NEWLINE_xXHad a solid organ or hematologic transplant.Xx_NEWLINE_xXHistory of organ transplant.Xx_NEWLINE_xXHistory of renal or liver transplantXx_NEWLINE_xXPatients who are transplanted at non-US transplant centersXx_NEWLINE_xXHas had a prior solid organ transplant.Xx_NEWLINE_xXPatients must be considered transplant eligible by the treating physician at time of study entry.Xx_NEWLINE_xXPrior organ transplant requiring immunosuppressive therapy.Xx_NEWLINE_xXParticipants that have had bone marrow or solid organ transplant are excluded.Xx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXWe will exclude patients who are eligible for an allogeneic bone marrow transplant at the time of study enrollment; if an enrolled patient subsequently becomes eligible for transplant, they will not be prevented from proceeding to the appropriate clinical treatment indicatedXx_NEWLINE_xXPatients who have failed a prior autologous transplant are eligible; however, at least 90 days must have elapsed between the start of this reduced intensity conditioning regimen and the last transplant if patient had a prior autologous BMTXx_NEWLINE_xXPatients who have undergone a prior allogeneic hematopoietic or (other organ) transplantXx_NEWLINE_xXHas had an allogeneic tissue/solid organ transplant.Xx_NEWLINE_xXAutologous transplant must have been done 100 days prior to the study enrollmentXx_NEWLINE_xXPatients who have undergone a bone marrow or solid organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHad a solid organ or hematologic transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXSubjects who have had solid organ transplantXx_NEWLINE_xXPatient must not be a candidate for liver transplant.Xx_NEWLINE_xXHas a history of clinically severe autoimmune disease, or history of organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXAny prior or planned organ transplant (e.g. liver transplant)Xx_NEWLINE_xXHistory of allogeneic organ transplant.Xx_NEWLINE_xXNo history of organ allograftXx_NEWLINE_xXHistory of organ transplantXx_NEWLINE_xXReceipt of solid organ transplantXx_NEWLINE_xX> 6 months since previous autologous transplant (if applicable)Xx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): History of having received an allogeneic bone marrow or organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplant (e.g. solid organ/bone marrow transplant patients)Xx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXHistory of allogeneic tissue or solid organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPatients must be at least 90 days post-transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant) except stem cell transplantsXx_NEWLINE_xXHistory of allogeneic organ transplant.Xx_NEWLINE_xXHistory of organ allograft, stem cells or bone marrow transplantXx_NEWLINE_xXHistory of clinically severe (e.g., requires chronic immunosuppressive therapy, [e.g., cyclosporine A, tacrolimus]) autoimmune disease (e.g., ulcerative colitis, lupus), or history of organ transplantXx_NEWLINE_xXHistory of allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant.Xx_NEWLINE_xXPrior allogeneic stem cell transplant or solid organ transplantXx_NEWLINE_xXPrevious allogeneic bone marrow transplantXx_NEWLINE_xXReceived a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplantXx_NEWLINE_xXPatients with a history of solid organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPrior allogeneic bone marrow transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of organ transplant.Xx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXLess than 3 months since prior myeloablative transplant (if applicable); less than 6 months since prior autologous transplant (if applicable)Xx_NEWLINE_xXHas undergone an organ transplant that requires use of immunosuppressive treatmentXx_NEWLINE_xXPresence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft; patients with a history of allogeneic hematopoietic stem cell transplant will also be excludedXx_NEWLINE_xXBoth transplant and non-transplant candidates are eligibleXx_NEWLINE_xXPatients with organ allografts (such as renal transplant) are excludedXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHad a solid organ or hematologic transplantXx_NEWLINE_xXPrior treatments: patients must have had at least one prior therapy\r\n* Patients with previous autologous transplant are permitted\r\n* Patients who are eligible and willing to undergo autologous transplant should not be enrolled on this trial\r\n* Prior allogeneic transplant is NOT permitted\r\n* Prior treatment with Bruton’s tyrosine kinase (BTK) inhibitors is NOT permitted\r\n* Prior treatment with nivolumab is permittedXx_NEWLINE_xXThe patient must be approved for transplant by the treating transplant physician. This includes completion of their pre-transplant workup, as directed by standard Dartmouth Hitchcock Medical Center (DHMC) standard of procedure (SOP)s (DHMC SOP – Pre-transplant Evaluation of allogeneic recipient)Xx_NEWLINE_xXTransaminases < 3 x normal at the time of transplantXx_NEWLINE_xXHad a solid organ or hematologic transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of organ transplant that requires use of immunosuppressivesXx_NEWLINE_xXHas had an allogeneic tissue/solid organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXDisease status defined as:\r\n* Patients with relapsed or refractory DLBCL that has relapsed post-transplant or that has been determined to be ineligible or unsuitable for transplant; patients must have to have received at least one prior systemic therapyXx_NEWLINE_xXPrior allogeneic solid organ transplantXx_NEWLINE_xXCurrently receiving or ever received immunosuppressive therapy for an autoimmune disorder or an organ transplantXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXPatients with progressive disease at time of transplantXx_NEWLINE_xXPatients with organ allografts (such as renal transplant) are excludedXx_NEWLINE_xXPatient with history of prior solid organ or allogeneic bone marrow transplantXx_NEWLINE_xXHistory of allogeneic organ transplant or autoimmune diseaseXx_NEWLINE_xXPatients with prior transplant of any kind are not eligibleXx_NEWLINE_xXPrior solid organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXPatients who have a history of an allogeneic tissue/solid organ transplant are not eligibleXx_NEWLINE_xXPatients with previous solid organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXMalignancy attributed to prior solid organ transplantXx_NEWLINE_xXDeemed to be not otherwise eligible for a myeloablative hematopoietic cell transplant; high risk characteristics for a myeloablative transplant include age > 60 years and a HCT comorbidity index > 3Xx_NEWLINE_xXPrior organ transplant or autoimmune disease requiring immunosuppressive therapyXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPrior solid organ transplant requiring immunosuppressive therapyXx_NEWLINE_xXLess than 3 months since prior myeloablative transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXMust be >= 3 months after prior myeloablative transplant, if applicableXx_NEWLINE_xXPatients with or without previous myeloablative autologous transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: History of organ allograft (including corneal transplant)Xx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of organ transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant).Xx_NEWLINE_xXConsidered transplant-eligible, as determined by the opinion of the investigator at the participating institution; the participating institution does not need to be a transplant center but patients can be referred to a transplant center if neededXx_NEWLINE_xXHas had an allogeneic tissue/solid organ transplantXx_NEWLINE_xXPrior organ transplant requiring immunosuppressive therapyXx_NEWLINE_xXParticipants who are less than 100 days post-transplant, or greater than 100 days post-transplant with active graft versus host disease (GVHD), or are still continuing post-transplant immunosuppressant therapy within 7 days prior to the first dose of study drug.Xx_NEWLINE_xXPrior allogenic transplantXx_NEWLINE_xXPrior organ allograftXx_NEWLINE_xXPrior allogeneic transplant with graft-versus-host disease (GVHD) requiring ongoing immunosuppressive therapyXx_NEWLINE_xXHistory of organ allograft including corneal transplantXx_NEWLINE_xXHistory of organ transplant.Xx_NEWLINE_xXPatients may not have had a prior autologous or allogeneic transplantXx_NEWLINE_xXWillingness to have an allogeneic transplantXx_NEWLINE_xXPatients with organ allografts (such as renal transplant) are excludedXx_NEWLINE_xXTime to initiation of maintenance therapy: patients may start maintenance therapy as early as 60 days post-transplant and up to 210 days post-transplant; as long as they meet the following criteria:Xx_NEWLINE_xXPatients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trialXx_NEWLINE_xXPatients with organ allografts (such as renal transplant) are excludedXx_NEWLINE_xXPrior solid organ transplantXx_NEWLINE_xXAnti-graft-versus-host disease (GVHD) or agents to prevent organ rejection post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trialXx_NEWLINE_xXHistory of solid organ or stem cell transplant requiring immunosuppressive medicationsXx_NEWLINE_xXHave undergone a prior allogeneic bone marrow transplant (BMT)Xx_NEWLINE_xXHistory of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization* or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy.Xx_NEWLINE_xXPART 2: Comorbidity Index < 5 at the time of pre-transplant evaluationXx_NEWLINE_xXPART 1: History of prior allogeneic transplantXx_NEWLINE_xXMajor anticipated illness or organ failure incompatible with survival form transplantXx_NEWLINE_xXHistory of organ transplant requiring therapeutic immunosuppressionXx_NEWLINE_xXPrior allogeneic transplant with graft-versus-host disease (GVHD) requiring immunosuppressive therapyXx_NEWLINE_xXRecipients of prior autologous or allogeneic transplant are eligible, as long as at least 3 months have passed since the transplant, and the patient fulfills other eligibility criteriaXx_NEWLINE_xXLiver transplant.Xx_NEWLINE_xXHistory of an allogeneic solid organ transplant or bone marrow transplant, or current active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.Xx_NEWLINE_xXMust not have undergone a prior allogeneic donor (related, unrelated, or cord) transplant; prior autologous transplant is not exclusionaryXx_NEWLINE_xXPrior transplant within 100 daysXx_NEWLINE_xXPrior allogeneic hematopoietic SCT within the last 12 months or reduced-intensity transplant within the past 6 monthsXx_NEWLINE_xXPatients are eligible to start on this protocol if they are between 6 months to 10 months post transplantXx_NEWLINE_xXPatients with prior history of severe (grade III or IV) acute GVHD even if resolved if post-transplantXx_NEWLINE_xXUndergone an organ transplant that requires use of immunosuppressive treatmentXx_NEWLINE_xXProgressive disease at transplant work-upXx_NEWLINE_xXPrior autologous or allogeneic transplantXx_NEWLINE_xXBone marrow comprising of < 10% lymphoma on most recent biopsy/aspiration (within 9 months of Allo transplant; may have been performed prior to autologous transplant)Xx_NEWLINE_xXPrior hematopoietic cell transplant: must be >= 3 months after previous transplantXx_NEWLINE_xXSecond hematopoietic cell transplant: Must be >= 3 months after prior myeloablative transplantXx_NEWLINE_xXAllogeneic transplant with a human leukocyte antigen (HLA)-identical sibling will be recommended for patients < 55 years; if the patient refuses allogeneic transplant, they may still be eligible for this protocolXx_NEWLINE_xXAdditional Eligibility Prior to Transplant Two:Xx_NEWLINE_xXTransplant able to occur between day +30 and day +90 from transplant oneXx_NEWLINE_xXMyeloablative transplant within the last 6 monthsXx_NEWLINE_xXIf =< 18 years old, prior myeloablative transplant within the last 6 months; if > 18 years old prior myeloablative allotransplant or autologous transplantXx_NEWLINE_xXSecond BMT: must be >= 3 months after prior myeloablative transplantXx_NEWLINE_xXHistory of organ allograft (allogeneic bone marrow or stem cell transplant) within 4 months prior to first dose of study drugXx_NEWLINE_xXReceived an allogeneic hematopoietic transplant within 3 months of screeningXx_NEWLINE_xXReceived immunosuppression post hematopoietic transplant within 1 month of study entryXx_NEWLINE_xXHistory of organ transplant that requires use of immunosuppressivesXx_NEWLINE_xXIf =< 18 years old, prior myeloablative transplant within the last 6 months; if >18 years old prior myeloablative allotransplant or autologous transplantXx_NEWLINE_xXHistory of solid organ transplantXx_NEWLINE_xXHistory of immunodeficiency, solid organ transplant, or tuberculosisXx_NEWLINE_xXHas a history of a bone marrow or solid organ transplant.Xx_NEWLINE_xXPatients not expected to be available for follow-up for at least 114 days after transplantXx_NEWLINE_xXPatients who receive post-transplant high dose cyclophosphamideXx_NEWLINE_xXPatients who have had a prior autologous transplant are eligibleXx_NEWLINE_xXPrevious organ transplantXx_NEWLINE_xXHas had an allogenic tissue/solid organ transplantXx_NEWLINE_xXreceived the transplant < 6 months prior to study Day 1Xx_NEWLINE_xXSubjects who have a known immunocompromised condition (HIV+, use of immunosuppressive medications or systemic steroids, organ transplant recipients)Xx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Patients who received prior allogeneic transplant are not eligibleXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Patients who received prior allogeneic transplant are not eligibleXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of solid organ transplantation (with the exception of a corneal transplant > 3 months prior to screening)Xx_NEWLINE_xXPrior organ transplant requiring immunosuppressive therapyXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXAllogeneic transplant for AML within the previous 6 months (no time limit for autologous transplant)Xx_NEWLINE_xXHistory of allogeneic organ transplant.Xx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of solid organ or stem cell transplant requiring immunosuppressive medicationsXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXPrior liver transplantXx_NEWLINE_xXTreatment with prior autologous transplant is permittedXx_NEWLINE_xXHistory of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of IMPXx_NEWLINE_xXPrior allogeneic stem cell transplant or solid organ transplantXx_NEWLINE_xXAnti-GVHD or agents to prevent organ rejection post-transplant; patients who are receiving cyclosporine, tacrolimus, or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial; at least 3 half-lives must have elapsed after the last dose of GVHD medications (meds)Xx_NEWLINE_xXHistory of organ allograft including corneal transplantXx_NEWLINE_xXPrior allogeneic stem cell transplant or solid organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPatients with history of organ transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXMust be >= 3 months after prior myeloablative transplant, if applicableXx_NEWLINE_xXSolid organ transplantXx_NEWLINE_xXTransplant < 4 months prior to study enrollmentXx_NEWLINE_xXDemonstrate adequate organ function per institutional guidelines for high-dose melphalan and autologous transplant at the time of enrollmentXx_NEWLINE_xXSubjects with multiple myeloma (MM), Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL) who are considered eligible for high-dose chemotherapy and autologous PBSC transplant by the transplant team at Kansas University Cancer Center (KUCC); subjects should be enrolled within 30 days of transplantXx_NEWLINE_xXPatients with an allogeneic transplant must meet the following conditions: the transplant must have been performed more than 90 days before registration to this study, the patient must not have >= grade 2 acute graft versus host disease (GvHD) or either moderate or severe limited chronic GvHD, or extensive chronic GvHD of any severity; the patient must be off all immunosuppression for at least 2 weeksXx_NEWLINE_xXRelapse must have occurred >= 60 days after transplantXx_NEWLINE_xXPatients who have received a prior autologous or allogeneic transplant are excludedXx_NEWLINE_xXHistory of allogenic transplantXx_NEWLINE_xXHistory of allogenic transplantXx_NEWLINE_xXPrevious allogeneic (allo)-transplant of any kindXx_NEWLINE_xXPatients with prior autologous or allogeneic transplant are eligible; patients must be > 100 days post transplant and have no evidence of active GVHDXx_NEWLINE_xXPrior allogeneic transplant for any hematopoietic disorderXx_NEWLINE_xXCord blood transplantXx_NEWLINE_xXUse of mammalian target of rapamycin (mTOR) inhibitors prior to transplant and as post-transplant immunosuppressionXx_NEWLINE_xXHas had a solid organ or hematologic transplant.Xx_NEWLINE_xXAutologous or allogenic transplant within the 60 days prior to Screening.Xx_NEWLINE_xXHas had a prior solid organ transplant.Xx_NEWLINE_xXPatients must not have any history of organ transplant that requires use of immunosuppressivesXx_NEWLINE_xXSubject has a history of organ transplant or allogeneic bone marrow transplant;Xx_NEWLINE_xXHas had a prior solid organ transplant.Xx_NEWLINE_xXPrior liver transplantXx_NEWLINE_xXPatients within 60 days of allogenic bone transplant are not eligible; patients with solid organ transplant are not eligibleXx_NEWLINE_xXHave had a liver transplant.Xx_NEWLINE_xXAutologous or allogenic transplant within the 60 days prior to the Screening visit.Xx_NEWLINE_xXKnow history of allografts (including corneal transplant).Xx_NEWLINE_xXSubject is likely to be considered for allogeneic transplant in the opinion of the transplant physician (based on age of patient, health, cytogenetics, and/or molecular characteristics)Xx_NEWLINE_xXHigh-risk AML for which transplant is recommend based on cytogenetic, molecular and morphologic features; patients must meet institutional standards for disease control prior to transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXOrgan transplant recipients other than bone marrow transplant;Xx_NEWLINE_xXOther immunocompromised status (e.g. organ transplant)Xx_NEWLINE_xXStatus post solid organ transplant.Xx_NEWLINE_xXPatient has received an organ transplantXx_NEWLINE_xXPrior allogeneic bone marrow or solid organ transplantXx_NEWLINE_xXHad a solid organ or hematologic transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPatients with history of organ transplantXx_NEWLINE_xXHas a transplanted organ or has undergone allogeneic bone marrow transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant).Xx_NEWLINE_xXPatients with organ allografts (such as renal transplant) are excludedXx_NEWLINE_xXUndergone a bone marrow or solid organ transplant.Xx_NEWLINE_xXAllogenic tissue/solid organ transplantXx_NEWLINE_xXHistory of organ transplantXx_NEWLINE_xXHistory of allogeneic tissue/solid organ transplantXx_NEWLINE_xXPrevious organ transplantXx_NEWLINE_xXSubject has had a liver transplantXx_NEWLINE_xXGraft vs. host disease following prior allogeneic transplant within 3 months prior to study treatment.Xx_NEWLINE_xXHistory or evidence of melanoma associated with immunodeficiency states (eg, hereditary immune deficiency, organ transplant, or leukemia)Xx_NEWLINE_xXPatients may have had autologous transplant; they must be at least 100 days post transplant, and have had recovery of their counts with absolute neutrophil count (ANC) > 1000 and platelets greater than 100 K at some point post-transplant, and be without active cytomegalovirus (CMV) or fungal diseaseXx_NEWLINE_xXPatients eligible, at the time of starting treatment, for curative therapeutic approaches (such as allogeneic transplant) are not eligible for the trial; however, patients who achieve CR or partial response (PR) as a result of therapy on this trial may proceed to allogeneic transplantXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXPrior organ transplant requiring immunosuppressive therapyXx_NEWLINE_xXSubject has received an organ transplantXx_NEWLINE_xXPatients who have previously received a solid organ transplant are not eligibleXx_NEWLINE_xXHistory of allogeneic bone marrow, stem cell, or solid organ transplantXx_NEWLINE_xXHistory of allogenic organ transplant.Xx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPrior allogeneic bone marrow transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPatients with an organ transplant, including those that have received an allogeneic bone marrow transplant.Xx_NEWLINE_xXSubject has a history of organ allograft including liver transplant.Xx_NEWLINE_xXPrior bone marrow transplant or history of organ transplant requiring the need for any chronic immunosuppressive medicationsXx_NEWLINE_xXPatients with organ allografts (such as renal transplant) are excludedXx_NEWLINE_xXPatients who have had a prior transplantXx_NEWLINE_xXHistory of organ transplant that requires use of immunosuppressive medicationsXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXHistory of major organ transplant.Xx_NEWLINE_xXHistory of having received an allogeneic bone marrow or organ transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXHas had an allogeneic tissue/solid organ transplantXx_NEWLINE_xXOrgan transplant (allograft) recipientXx_NEWLINE_xXOrgan transplant (allograft) recipientXx_NEWLINE_xXPrevious organ transplantXx_NEWLINE_xXThe patient must be approved for transplant by the treating Transplant physician; this includes completion of their pre-transplant workup, as directed by standard DHMC SOPsXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXSeverely immunocompromised patients (eg transplant, on immunosuppressive drugs)Xx_NEWLINE_xXHistory of an allogeneic solid organ transplant or bone marrow transplant, or current active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.Xx_NEWLINE_xXPrevious allogeneic bone marrow transplant.Xx_NEWLINE_xXSubjects who are anticipated to receive a transplant within the first 6 months of treatment on trialXx_NEWLINE_xXPresence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft; patients with a history of allogeneic hematopoeitic stem cell transplant will be excludedXx_NEWLINE_xXPrior allogeneic HCT (prior autologous transplant is allowed regardless of response)Xx_NEWLINE_xXPrior allogeneic transplant of any kindXx_NEWLINE_xXHistory of organ allograft. (Including corneal transplant)Xx_NEWLINE_xXParticipants must not have had a prior transplantXx_NEWLINE_xXPrior autologous or allogeneic transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXEligible for allogeneic transplant in the treating physicians’ judgment and by institutional standardsXx_NEWLINE_xXELIGIBILITY TO RECEIVE DLI POST-TRANSPLANT:Xx_NEWLINE_xXHistory of organ transplant.Xx_NEWLINE_xXHistory of any organ or bone marrow transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXHistory of organ transplant, or current active immunosuppressive therapy (such as cyclosporine, tacrolimus, etc.).Xx_NEWLINE_xXTime to initiation of maintenance therapy; patients may start maintenance therapy as early as 60 days post-transplant and up to 180 days post-transplant; as long as they meet the following criteria:Xx_NEWLINE_xXHistory of organ transplant that requires use of immunosuppressivesXx_NEWLINE_xXPrior myeloablative transplant within previous 3 months of study enrollmentXx_NEWLINE_xXPrior solid organ transplantXx_NEWLINE_xXAML relapsed > 2 months after transplantXx_NEWLINE_xXTransplant < 60 days prior to study enrollmentXx_NEWLINE_xXAllogeneic transplant for AML within previous 6 months (no time limit for autologous transplant)Xx_NEWLINE_xXTRANSPLANT RECIPIENTXx_NEWLINE_xXIf patients are found to not be in remission at screening, then the patient may be returned to their primary hematologist/oncologist or may receive chemotherapy as per standard of care for the malignant disease; patients for whom this would be their first allogeneic transplant must be in remission (< 5% malignant blasts in marrow and peripheral blood and no evidence of extramedullary disease) for transplant; patients enrolled on this protocol for their second transplant do not need to have attained remission prior to transplantXx_NEWLINE_xXTRANSPLANT RECIPIENT:Xx_NEWLINE_xX18F FLT CANDIDATE TRANSPLANT RECIPIENT: Meets criteria for transplant recipientsXx_NEWLINE_xXHistory of organ allograftXx_NEWLINE_xXHistory of liver transplant requiring increased immunosuppressive therapy. (Participants on maintenance immunosuppressive therapy after liver transplant are eligible for Part A & B)Xx_NEWLINE_xXHistory of organ allograftXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPatients who have undergone prior allogeneic transplant are excluded only if they remain on any immunosuppression or have signs or symptoms of clinical graft-versus-host diseaseXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHas a history of clinically severe autoimmune disease, or history of organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXPreviously received an allogeneic transplantXx_NEWLINE_xXPRIOR TO POST-TRANSPLANT IMMUNOTHERAPY: Resolution of all transplant related grade III-IV toxicityXx_NEWLINE_xXPRIOR TO POST-TRANSPLANT IMMUNOTHERAPY: WBC >= 2.0 X 10^3/uLXx_NEWLINE_xXPRIOR TO POST-TRANSPLANT IMMUNOTHERAPY: Bilirubin =< 2.0 mg/dLXx_NEWLINE_xXPrior allogeneic SCT or organ transplant (Arms A and D only)Xx_NEWLINE_xXPatients must be in complete remission post transplantXx_NEWLINE_xXPatient may be enrolled 40 to 100 days after transplantXx_NEWLINE_xXMRD will be defined as detection in blood or marrow of:\r\n* Any leukemia specific marker (such as t[9:22] or t[4:11]) documented in the patient’s leukemia cells pre transplant on a post-transplant evaluation\r\n* A T-cell receptor (TCR) or immune globulin rearrangement known to be a disease marker for this patient post-transplant\r\n* A leukemia specific phenotype post-transplant at a level of >= 0.01%\r\n* Mixed donor chimerism; OR\r\n* With no evidence of ALL or CLL/NHL post-HSCT (to be included in the phase II extension)Xx_NEWLINE_xXAutologous or allogeneic bone marrow transplant as second-line therapy.Xx_NEWLINE_xXTIER I SUBJECTS: Patients who have had an autologous transplant must wait at least 180 days from day 0 of autologous transplant to be eligible; patients do not have to relapse following transplant to be eligible provided they meet the 180 day wait post day 0 of transplant requirement; transplant date is defined as the day of infusion of stem cellsXx_NEWLINE_xXPatients must have a corrected diffusion capacity >= 50% prior to the autologous transplant and >= 40% prior to the allogeneic transplantXx_NEWLINE_xXPlanned organ transplant during the studyXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant).Xx_NEWLINE_xXPatients who are deemed eligible for transplant by their treating physicianXx_NEWLINE_xXMust be transplant-eligible per institution guidelinesXx_NEWLINE_xXHave progressive disease at the time of transplantXx_NEWLINE_xXTransplant eligible patients are eligibleXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXTransplant within 8 weeksXx_NEWLINE_xXPatients wanting to pursue transplantXx_NEWLINE_xXHistory of organ transplant.Xx_NEWLINE_xXAutologous transplant < 12 months prior to enrollment.Xx_NEWLINE_xXPrior autologous transplant for the disease for which the UCB transplant is being performed.Xx_NEWLINE_xXRelapsed within three months post-transplantXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXHistory of organ transplant that requires use of immunosuppressivesXx_NEWLINE_xXPatients cannot be on a transplant listXx_NEWLINE_xXHistory of organ allograftXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xX> 60 days after reduced intensity conditioning (RIC) allogeneic transplant for lymphomaXx_NEWLINE_xXPrior organ transplant requiring immunosuppressive therapyXx_NEWLINE_xXPrior myeloablative transplant within the last 6 monthsXx_NEWLINE_xXHistory of the following therapies in the post-transplant period:Xx_NEWLINE_xXPatient has received an HSCT transplant for a solid tumor disease.Xx_NEWLINE_xXHistory of solid organ transplantation (with the exception of a corneal transplant > 3 months prior to screening).Xx_NEWLINE_xXUndergone a liver or other organ transplantXx_NEWLINE_xXSubjects who have received any type of solid organ transplantXx_NEWLINE_xXTransplant was more than (>) 100 days prior to study enrollmentXx_NEWLINE_xXHistory of major organ transplantXx_NEWLINE_xXHistory of liver transplant.Xx_NEWLINE_xXPatients who have undergone hematopoietic cell transplant (HCT), solid organ transplant (SOT)Xx_NEWLINE_xXEnrollment on any other transplant related protocolsXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXRecent salvage transplant (=< 6 months but >= 45 days post-transplant prior to study enrollment) for relapseXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXPatients with known HIV or with solid organ transplantXx_NEWLINE_xXHistory of liver transplantXx_NEWLINE_xXHistory of solid organ transplant or bone marrow transplantXx_NEWLINE_xXPatients who have received organ transplantXx_NEWLINE_xXHad an autologous transplant within 3 months of starting study drug treatment.Xx_NEWLINE_xXIs within 2 months of transplant from C1D1Xx_NEWLINE_xXHad a prior liver transplant or is planned to undergo liver transplant during the study period;Xx_NEWLINE_xXFour months post liver transplantXx_NEWLINE_xXThe transplant occurred > 6 months agoXx_NEWLINE_xXOrgan transplant recipientXx_NEWLINE_xXHistory of organ allograftXx_NEWLINE_xXTransplant ineligibilityXx_NEWLINE_xXHistory of organ transplantXx_NEWLINE_xXHistory of liver transplantXx_NEWLINE_xXReceiving an organ transplant during the same surgical procedure.Xx_NEWLINE_xXEligible for allogeneic bone marrow transplant.Xx_NEWLINE_xXReceipt of an allogeneic transplant.Xx_NEWLINE_xXTreatment with prior autologous transplant is permittedXx_NEWLINE_xXHave a history of major organ transplant (for example: heart, lungs, liver, and kidney)Xx_NEWLINE_xXPatients with prior allogeneic transplant are not eligible.Patients with a documented history of cerebrovascular accidents and/or TIA within the past 6 months are not eligible.Xx_NEWLINE_xXHistory of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of study drug.Xx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXPatients will be eligible to enter the study between 60-120 days post-transplantXx_NEWLINE_xXPatients who were treated with 5'-azacitidine without response prior to transplant would be eligible to participate on this protocolXx_NEWLINE_xXHistory of major organ transplantXx_NEWLINE_xXHistory of organ allograft.Xx_NEWLINE_xXPrevious allogenic hematopoietic transplant within 90 dXx_NEWLINE_xXPrevious allogeneic hematopoietic transplant within 90 days of study enrollment, Active GVHD requiring treatment.Xx_NEWLINE_xXPrevious allogeneic hematopoietic transplant within 90 days. Active GVHD requiring treatmentXx_NEWLINE_xXHistory of having received allogeneic organ transplantXx_NEWLINE_xXPreviously received an allogeneic transplant.Xx_NEWLINE_xXAny prior allogeneic transplant.Xx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXHistory of organ transplant requiring therapeutic immunosuppressionXx_NEWLINE_xXPatients with organ allografts (such as renal transplant) are excludedXx_NEWLINE_xXHistory of organ allograft (including corneal transplant)Xx_NEWLINE_xXPatients who have undergone any prior transplantXx_NEWLINE_xXPatient may have had prior autologous or allogeneic transplant (family member, unrelated donor, or cord blood) if there is at least 90 days between transplant and study entryXx_NEWLINE_xXPatients who have previously received an autologous SCT, are excluded if less than 90 days have elapsed from the time of transplant or the patient has not recovered from transplant-associated toxicities prior to the first scheduled dose of MEDI7247.Xx_NEWLINE_xXHas had previous allogeneic tissue/solid organ transplantXx_NEWLINE_xXHas undergone a liver transplant, kidney transplant or nephrectomy.Xx_NEWLINE_xXHas undergone a liver transplant, kidney transplant or nephrectomy.Xx_NEWLINE_xXHistory of allogenic organ transplantXx_NEWLINE_xXPhase I: Currently scheduled for autologous or allogeneic transplant at the Hospital of the University of PennsylvaniaXx_NEWLINE_xXReceived >= 1 autologous or allogeneic (related or unrelated) HCT with curative intent at a participating transplant center for a hematologic malignancyXx_NEWLINE_xXSubjects with a previous solid organ transplantXx_NEWLINE_xXAllogeneic transplant recipients undergoing ablative transplants will also be eligible to participate; those receiving nonablative regimens (a small proportion of allogeneic transplant recipients at UWCCC) will be excludedXx_NEWLINE_xXHistory (hx) of organ transplantXx_NEWLINE_xXPOST-TRANSPLANT STATUSXx_NEWLINE_xXTRANSPLANT PATIENTS: all patients undergoing planned allogeneic transplant (both malignant and non-malignant diagnoses)Xx_NEWLINE_xXAllogeneic transplant recipients undergoing fully ablative transplantsXx_NEWLINE_xXHistory of allogeneic bone marrow, stem cell, or solid organ transplantXx_NEWLINE_xXOrgan Transplant: Patients may NOT be the recipients of an organ transplant.Xx_NEWLINE_xXLiver transplant.Xx_NEWLINE_xXOrgan transplant (allograft) recipientXx_NEWLINE_xXPatient must not have had a previous allogeneic or syngeneic transplant; prior autologous transplant is allowedXx_NEWLINE_xXPatients must have a pre-transplant multi-organ assessment with the following outcome:Xx_NEWLINE_xXAdult (? 18 years at time of allogeneic HCT recipient at participating transplant centers)Xx_NEWLINE_xXAll transplant types will be eligible (autologous or allogeneic related or unrelated)Xx_NEWLINE_xXPatients who have received their transplant at a different transplant center will not be eligible for the studyXx_NEWLINE_xXGENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have had a prior solid organ transplant are not eligibleXx_NEWLINE_xXAllogeneic HSCT recipients who are 3-35 months post-transplantXx_NEWLINE_xXPrior allotransplant, including allogeneic hematopoietic cell transplant or solid organ allogeneic transplantXx_NEWLINE_xXPrior organ transplantXx_NEWLINE_xXAllogeneic HSCT recipients who are 3-23 months post-transplantXx_NEWLINE_xXPatients who have received an autologous transplantXx_NEWLINE_xXPrior liver transplantXx_NEWLINE_xXPatients who have failed a prior autologous or allogeneic transplant are eligible; however, at least 6 months must have elapsed between the start of this reduced intensity conditioning regimen and the last transplant if patient had a prior autologous or myeloablative allogeneic bone marrow transplant (BMT)Xx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXReceived solid organ transplant (kidney or other)Xx_NEWLINE_xX3-24 months post-transplant (any number of transplant)Xx_NEWLINE_xXChildren are not eligible as the transplant program is certified as an adult only transplant programXx_NEWLINE_xXReceived post-transplant cyclophosphamideXx_NEWLINE_xXPrior liver transplantXx_NEWLINE_xXPatients must have undergone an autologous transplant =< 12 months prior to transplant on this study or have received multi-agent or immunosuppressive chemotherapy within 3 months of the preparative regimenXx_NEWLINE_xXPrior solid organ or bone marrow transplantXx_NEWLINE_xXUnderwent a previous related or unrelated allogeneic transplantXx_NEWLINE_xXSubjects who have received any type of solid organ transplantXx_NEWLINE_xXHistory of allogeneic organ transplantXx_NEWLINE_xXSubject who is scheduled to have a cord blood transplant or a haploidentical transplantXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXPrior allogeneic transplantXx_NEWLINE_xXIn order to identify subjects at risk for the development of NSF, the American College of Radiology (http://acr.org) recommends obtaining a medical history and a glomerular filtration rate (GFR) assessment within six weeks of MR imaging in the following patients: \r\n* Renal disease (including solitary kidney, renal transplant, renal tumor)\r\n* Age > 60\r\n* History of hypertension\r\n* History of diabetes\r\n* History of severe hepatic disease/liver transplant/pending liver transplantXx_NEWLINE_xXPrior liver transplantXx_NEWLINE_xXPatients who have received a prior allogeneic transplant will be excludedXx_NEWLINE_xXPatients who, with their treating physician, choose to proceed with an allogeneic transplant at the time of remission will not be eligible for randomizationXx_NEWLINE_xXHas previously had a hematopoetic stem cell transplant or solid organ transplantXx_NEWLINE_xXSubject has had prior allogeneic transplant.Xx_NEWLINE_xXHas received an allogeneic transplant in the past; scheduled to receive a second allogeneic transplantXx_NEWLINE_xXPrior organ transplantXx_NEWLINE_xXAutologous or allogenic transplant within the 60 days prior to Screening.Xx_NEWLINE_xX